缓激肽

Bradykinin

未知生产厂商

Bradykinin has been investigated for the basic science and treatment of Hypertension and Diabetes Type 2.

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Bradykinin has been investigated for the basic science and treatment of Hypertension and Diabetes Type 2.

技术标识符

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

ANTIBODIES TO BRADYKININ B1 RECEPTOR LIGANDS
EP 3246339 B1申请人: SANOFI SA优先权: 2012
CN
EP
US
WO
15 件公开
Antagonists of the bradykinin B1 receptor
US 2005215470 A1申请人: AMGEN INC优先权: 2004
US
6 件公开
SOLID EXTENDED-RELEASE COMPOSITION COMPRISING BRADYKININ B2-RECEPTOR ANTAGONISTS
EP 4684830 A3申请人: PHARVARIS GMBH优先权: 2022
CN
EP
US
WO
5 件公开
EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS
EP 4234583 A3申请人: TAKEDA PHARMACEUTICALS CO优先权: 2013
CN
EP
US
5 件公开
Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor
- US 11905270 B2
  申请人: BAYER PHARMA AG优先权: 2016
  CN
  US
  5 件公开
- US 12239630 B2
  申请人: BAYER PHARMA AG优先权: 2023
  US
Sulfonylquinoxalone derivatives as bradykinin antagonists
US 7056937 B2申请人: ELAN PHARM INC优先权: 2003
US
5 件公开
LIPID-BASED COMPOSITION FOR ORAL ADMINISTRATION OF BRADYKININ B2-RECEPTOR ANTAGONISTS
EP 4203919 B1申请人: PHARVARIS GMBH优先权: 2021
CN
EP
US
WO
4 件公开
SOLID COMPOSITION COMPRISING SOLUBILISED BRADYKININ B2-RECEPTOR ANTAGONISTS
EP 4499038 C0申请人: PHARVARIS GMBH优先权: 2022
CN
EP
US
WO
4 件公开
8-oxy-quinoline derivatives as bradykinin B2 receptor modulators
US 8410134 B2申请人: GIBSON CHRISTOPH优先权: 2007
CN
EP
US
4 件公开
NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS
EP 3998259 A1申请人: PHARVARIS NETHERLANDS B V优先权: 2017
CN
EP
US
4 件公开